Drug Profile
Research programme: cancer radiopharmaceuticals - Fusion Pharmaceuticals
Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Janssen Biotech
- Developer Fusion Pharmaceuticals
- Class Diagnostic agents; Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer